BioNTech Faces Legal Challenge Following Strategic Acquisition
07.01.2026 - 20:12:03 | boerse-global.de
BioNTech finds itself navigating a dual narrative this week, marked by a significant corporate milestone and the emergence of fresh legal headwinds. The German biotech firm has finalized its takeover of rival CureVac, a move that consolidates its position in the mRNA technology arena. Concurrently, the company, alongside partners Pfizer and Moderna, is confronting a new patent infringement lawsuit filed by Bayer.
The strategic consolidation within the mRNA sector reached its conclusion on Wednesday, January 7, 2026. BioNTech confirmed the completion of its acquisition of CureVac, following amendments to the articles of association and the squeeze-out of remaining minority shareholders. With this transaction, BioNTech now holds full ownership of CureVac’s Read more...
Hol dir jetzt den Wissensvorsprung der Aktien-Profis.
Für. Immer. Kostenlos
